Menu Search
Equities

Orthocell Ltd

OCC:ASX

Orthocell Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.63
  • Today's Change0.005 / 0.80%
  • Shares traded519.13k
  • 1 Year change+48.24%
  • Beta1.1160
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Orthocell Ltd had net income fall 14.93% from a loss of 6.25m to a larger loss of 7.18m despite a 32.79% increase in revenues from 5.09m to 6.76m. An increase in the cost of goods sold as a percentage of sales from 20.15% to 24.05% was a component in the falling net income despite rising revenues.
Gross margin75.95%
Net profit margin-106.16%
Operating margin-151.28%
Return on assets-25.55%
Return on equity-134.46%
Return on investment-30.96%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Orthocell Ltd fell by 4.20m. Cash Flow from Financing totalled 3.24m or 47.95% of revenues. In addition the company used 6.51m for operations while cash used for investing totalled 942.02k.
Cash flow per share-0.0338
Price/Cash flow per share--
Book value per share0.0217
Tangible book value per share0.0167
More ▼

Balance sheet in AUDView more

Orthocell Ltd has a Debt to Total Capital ratio of 13.21%, a higher figure than the previous year's 6.21%.
Current ratio4.34
Quick ratio4.11
Total debt/total equity0.1522
Total debt/total capital0.1321
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.